Thymosin α1 combined with XELOX improves immune function and reduces serum tumor markers in colorectal cancer patients after radical surgery

Thymosin α1 combined with XELOX improves immune function and reduces serum tumor markers in colorectal cancer patients after radical surgery

This study aimed to investigate the efficacy of thymosin α1 combined with XELOX in improving immune function and reducing serum tumor markers in patients with colorectal cancer (CRC) after radical surgery. A total of 180 patients who underwent radical surgery for CRC were divided into two groups: an...

Full description

Bibliographic Details
Main Authors: Sha Li, Zhang Hao, Zhang Xiwei
Format: Article
Language:English
Published: De Gruyter 2024-04-01
Series:Open Life Sciences
Subjects:
thymosin α1
oxaliplatin
capecitabine
colorectal cancer
immune function
tumor marker
radical surgery
Online Access:https://doi.org/10.1515/biol-2022-0793

Internet

https://doi.org/10.1515/biol-2022-0793

Similar Items